GW Pharmaceuticals PLC (NASDAQ:GWPH) Given Outperform Rating at Leerink Swann

GW Pharmaceuticals PLC (NASDAQ:GWPH)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Leerink Swann in a research report issued to clients and investors on Thursday. They presently have a $160.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $162.00. Leerink Swann’s price objective points to a potential upside of 59.17% from the company’s previous close.

Several other analysts have also issued reports on GWPH. Maxim Group lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating and set a $61.00 price objective on the stock. in a research note on Tuesday. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. BidaskClub upgraded GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 14th. Finally, TheStreet lowered GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $147.94.

Shares of GW Pharmaceuticals PLC (GWPH) opened at 100.52 on Thursday. The firm’s market cap is $2.54 billion. The firm has a 50-day moving average price of $107.01 and a 200-day moving average price of $113.94. GW Pharmaceuticals PLC has a 12-month low of $79.62 and a 12-month high of $137.88.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.73) by $0.34. The business had revenue of $3.14 million during the quarter, compared to the consensus estimate of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 27.57%. During the same quarter in the prior year, the company earned ($0.05) EPS. Equities research analysts anticipate that GW Pharmaceuticals PLC will post ($5.10) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “GW Pharmaceuticals PLC (NASDAQ:GWPH) Given Outperform Rating at Leerink Swann” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/08/10/gw-pharmaceuticals-plc-nasdaqgwph-given-outperform-rating-at-leerink-swann.html.

Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA purchased a new position in GW Pharmaceuticals PLC during the second quarter valued at approximately $163,000. Blair William & Co. IL purchased a new position in GW Pharmaceuticals PLC during the first quarter valued at approximately $207,000. Nwam LLC purchased a new position in GW Pharmaceuticals PLC during the first quarter valued at approximately $208,000. Ameriprise Financial Inc. purchased a new position in GW Pharmaceuticals PLC during the first quarter valued at approximately $230,000. Finally, Quantbot Technologies LP purchased a new position in GW Pharmaceuticals PLC during the first quarter valued at approximately $231,000. 75.77% of the stock is currently owned by institutional investors.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply